120 related articles for article (PubMed ID: 34965846)
1. Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer.
Henderson RH; Bryant CM; Nichols RC; Mendenhall WM; Hoppe BS; Su Z; Morris CG; Mendenhall NP
Acta Oncol; 2022 Apr; 61(4):468-477. PubMed ID: 34965846
[TBL] [Abstract][Full Text] [Related]
2. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
[TBL] [Abstract][Full Text] [Related]
3. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
[TBL] [Abstract][Full Text] [Related]
4. Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer.
Henderson RH; Bryant C; Hoppe BS; Nichols RC; Mendenhall WM; Flampouri S; Su Z; Li Z; Morris CG; Mendenhall NP
Acta Oncol; 2017 Jul; 56(7):963-970. PubMed ID: 28514929
[TBL] [Abstract][Full Text] [Related]
5. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer.
Choo R; Hillman DW; Mitchell C; Daniels T; Vargas C; Rwigema JC; Corbin K; Keole S; Vora S; Merrell K; Stish B; Pisansky T; Davis BJ; Amundson A; Wong W
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1085-1094. PubMed ID: 36427645
[TBL] [Abstract][Full Text] [Related]
6. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
7. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
[TBL] [Abstract][Full Text] [Related]
9. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
11. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer.
Mendenhall NP; Hoppe BS; Nichols RC; Mendenhall WM; Morris CG; Li Z; Su Z; Williams CR; Costa J; Henderson RH
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):596-602. PubMed ID: 24521677
[TBL] [Abstract][Full Text] [Related]
12. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
[TBL] [Abstract][Full Text] [Related]
13. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
[TBL] [Abstract][Full Text] [Related]
14. A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.
Lukez A; Handorf E; Mendenhall NP; Henderson RH; Stish BJ; Davis BJ; Hallman M; Horwitz EM; Vapiwala N; Wong JK
Prostate; 2024 Mar; 84(4):395-402. PubMed ID: 38108113
[TBL] [Abstract][Full Text] [Related]
15. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials.
Henderson RH; Hoppe BS; Marcus RB; Mendenhall WM; Nichols RC; Li Z; Su Z; Morris CG; Williams CR; Costa J; Mendenhall NP
Acta Oncol; 2013 Apr; 52(3):463-9. PubMed ID: 23477359
[TBL] [Abstract][Full Text] [Related]
16. Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon.
Deville C; Both S; Bui V; Hwang WT; Tan KS; Schaer M; Tochner Z; Vapiwala N
Radiat Oncol; 2012 May; 7():76. PubMed ID: 22621764
[TBL] [Abstract][Full Text] [Related]
17. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
18. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer.
Mendenhall NP; Li Z; Hoppe BS; Marcus RB; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Costa J; Henderson R
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):213-21. PubMed ID: 21093164
[TBL] [Abstract][Full Text] [Related]
19. Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy.
Kharod SM; Mercado CE; Morris CG; Bryant CM; Mendenhall NP; Mendenhall WM; Nichols RC; Hoppe BS; Liang X; Su Z; Li Z; Henderson RH
Int J Part Ther; 2021; 7(4):52-64. PubMed ID: 33829073
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.
Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S
Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]